ribavirin has been researched along with ginsenoside rb1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Fan, H; Gao, H; He, L; Kang, N; Liu, Y; Xu, Q; Yang, S | 1 |
2 other study(ies) available for ribavirin and ginsenoside rb1
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Ginsenoside Rb1 is an immune-stimulatory agent with antiviral activity against enterovirus 71.
Topics: Adjuvants, Immunologic; Animals; Antiviral Agents; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Enterovirus A, Human; Enterovirus Infections; Ginsenosides; Humans; Mice; Mice, Inbred ICR; Panax; Rhabdomyosarcoma; Ribavirin | 2021 |